Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
("Mediclinic", or the "Company" or the "Group")
22 July 2020
APPOINTMENT OF STEVE WEINER AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR
Mediclinic, a leading diversified international private healthcare services group, announces the appointment of Steve Weiner as an independent non-executive director and a member of the Audit and Risk and Clinical Performance and Sustainability committees with effect from 22 July 2020.
Mr Weiner is currently a non-executive director of Guys' and St Thomas' NHS Foundation Trust, one of the largest NHS Foundation Trusts in the UK, where he chairs the Transformation and Major Programmes Committee; is a member of the Strategy and Partnerships committee; and a member of the Audit Committee, which he chaired from 2014 to 2018. He is also a non-executive director and a member of the Finance and Commercial Committee of King's College Hospital NHS Foundation Trust, one of London's largest and busiest teaching hospitals. Prior to this, Mr Weiner spent most of his career in finance with the international consumer goods group Unilever, most recently as Group Controller responsible for performance management, accounting, reporting and control. He was also a member of Unilever's Global Finance Leadership Team, working closely with the group's board and Audit Committee.
Dame Inga Beale, Chair Designate of Mediclinic, commented:
"The Board is delighted to welcome Steve as an independent non-executive director of the Company, following a rigorous and thorough search process. He brings significant healthcare and international consumer goods experience in executive and non-executive finance and business transformation leadership roles in large, complex organisations in developed and developing markets. I am sure he will be a great addition to our Board of Directors."
Steve Weiner, independent non-executive director, commented:
"It gives me great pleasure to be joining the Board of Directors at Mediclinic. I have been impressed with the way the Group continues to adapt to the evolving healthcare landscape, creating opportunities across the continuum of care for the benefit of patients. I believe my broad expertise in the sector can support the advancement of this and other key strategic goals in the future."
Mr Weiner holds a Masters in Finance from Columbia University and a Bachelor of Science in Management from Rutgers University.
This announcement is made in accordance with the requirement of LR 9.6.11. There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the United Kingdom Listing Authority's Listing Rules in respect of this appointment.
CHANGES TO COMMITTEE MEMBERSHIPS
As announced on 24 July 2019, Dr Edwin Hertzog is retiring as a non-executive director and Chair of Mediclinic at the conclusion of the Company's 2020 Annual General Meeting, being held today and will be succeeded by Dame Inga Beale. Dr Hertzog will receive no remuneration payment or payment for loss of office in connection with his retirement other than his usual director's fee for the month of July 2020 and any expenses incurred in attending Board meetings.
The Board has agreed to certain changes to the membership of its committees reflecting Dr Hertzog's retirement and Mr Weiner's appointment, as follows:
Audit and Risk Committee:
Mr Weiner will be appointed as an additional member of the Audit and Risk Committee with effect from 22 July 2020.
With effect from 22 July 2020, Dr Hertzog will step down as Chair of the Nomination Committee and will be succeeded by Dame Inga Beale.
Clinical Performance and Sustainability Committee:
With effect from 22 July 2020, Dr Hertzog will step down as a member of the Clinical Performance and Sustainability Committee and Mr Weiner will be appointed as a member of the Committee from that date.
Dr Hertzog will step down as Chair and member of the Investment Committee with effect from 22 July 2020 and the Nomination Committee will consider the appointment of a new member to the Committee in due course.
There are no changes to the composition of the Remuneration Committee.
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 1 July 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and three day case clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE.
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
+44 (0)20 7954 9548
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd